EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Bioequivalence Study of Epalrestat for Healthy Chinese Subjects

Dandan Yang, Xiaodan Wang, Yi Duan, Yichao Xu, Zourong Ruan, Bo Jiang, Honggang Lou, Jinliang Chen

Clinical Pharmacology in Drug Development · 2024

DOI: 10.1002/cpdd.1347 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2024. Verfasst von Dandan Yang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center of Clinical Pharmacology, The Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Area Under Curve, Healthy Volunteers, Rhodanine, Therapeutic Equivalency. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epalrestat is a reversible noncompetitive inhibitor of aldose reductase with selective inhibition of aldose reductase. It can inhibit the accumulation of sorbitol in red blood cells in patients with diabetic peripheral neuropathy and can improve patients’ conscious symptoms and neurological dysfunction. This study was designed to evaluate the bioequivalence in healthy Chinese subjects of a new test formulation and reference formulation of oral epalrestat (50 mg) in the fasting state. The study was performed with 44 healthy Chinese subjects according to a randomized 2‐way crossover design. The main pharmacokinetic parameters of test formulation and reference formulation as follows: 4793 and 4781 ng/mL for maximum plasma concentration, 8556 and 8431 ng h/mL for area under the plasma concentration‐time curve extrapolated to infinity. The test formulation of epalrestat was bioequivalent to the reference formulation. The bioequivalence study of epalrestat in healthy Chinese subjects suggests that the test and reference formulations have similar pharmacokinetics and both formulations are well tolerated in the dose range studied in healthy Chinese subjects. All these findings provided valuable pharmacokinetic knowledge for further clinical development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Area Under CurveHealthy VolunteersRhodanineTherapeutic EquivalencyAdultFemaleHumansMaleYoung AdultAdministration, OralAldehyde ReductaseChinaCross-Over StudiesEast Asian PeopleEnzyme InhibitorsThiazolidines

Stichwörter der Autor:innen

bioequivalence studyclinical trialepalrestathealthy Chinese subjectspharmacokinetics

Substanzen

Aldehyde ReductaseEnzyme InhibitorsepalrestatRhodanineThiazolidines

Autor:innen und Institutionen

  • Center of Clinical Pharmacology, The Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China.

Zitieren

APA

Yang, D., Wang, X., Duan, Y., Xu, Y., Ruan, Z., Jiang, B., Lou, H., & Chen, J. (2024). Bioequivalence Study of Epalrestat for Healthy Chinese Subjects. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1347

Vancouver

Yang D, Wang X, Duan Y, Xu Y, Ruan Z, Jiang B, et al. Bioequivalence Study of Epalrestat for Healthy Chinese Subjects. Clinical Pharmacology in Drug Development. 2024. doi:10.1002/cpdd.1347

BibTeX
@article{Yang2024,
  author = {Yang, Dandan and Wang, Xiaodan and Duan, Yi and Xu, Yichao and Ruan, Zourong and Jiang, Bo and Lou, Honggang and Chen, Jinliang},
  title = {Bioequivalence Study of Epalrestat for Healthy Chinese Subjects},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2024},
  doi = {10.1002/cpdd.1347}
}
Kostenlos starten →